<p>有些人认为波动性，而不是债务，是投资者思考风险的最佳方式，但沃伦·巴菲特曾著名地说过：“波动性远非风险的同义词。” 因此，聪明的钱知道，债务——通常与破产相关联——在评估一家公司风险时是一个非常重要的因素。我们注意到 <strong>ZIM Laboratories Limited</strong> (NSE:ZIMLAB) 的资产负债表上确实有债务。但这对股东来说是个问题吗？</p>
<p>这项技术可能会取代计算机：发现 20 只正在努力使量子计算成为现实的股票。</p>
<h2>债务带来什么风险？</h2>
<p>债务在企业能够偿还时是有帮助的，无论是通过新资本还是自由现金流。如果情况变得非常糟糕，贷款方可能会控制企业。然而，更常见（但仍然痛苦）的情况是，公司不得不以低价筹集新的股本，从而永久性地稀释股东的权益。话虽如此，最常见的情况是公司合理管理其债务，并使其对自身有利。考虑公司债务水平的第一步是将其现金和债务一起考虑。</p>
<h2>ZIM Laboratories 的债务有多少？</h2>
<p>正如您在下面看到的，截至 2025 年 9 月底，ZIM Laboratories 的债务为 ₹1.17b，较一年前的 ₹973.5m 增加。点击图片以获取更多详细信息。另一方面，它有 ₹46.3m 的现金，导致净债务约为 ₹1.13b。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/58281653-debt-equity-history-analysis-1-dark-2/1768522290441?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/58281653-debt-equity-history-analysis-1-dark-2/1768522290441"/></p>
<p>NSEI:ZIMLAB 债务与股本历史 2026 年 1 月 16 日</p>
<h2>ZIM Laboratories 的资产负债表健康吗？</h2>
<p>我们可以从最新的资产负债表中看到，ZIM Laboratories 有 ₹1.60b 的负债在一年内到期，以及 ₹585.5m 的负债在此之后到期。抵消这些义务，它有 ₹46.3m 的现金以及价值 ₹1.02b 的应收账款将在 12 个月内到期。因此，它的负债总额比其现金和短期应收账款的总和多出 ₹1.12b。</p>
<p>这个赤字并不算太糟，因为 ZIM Laboratories 的市值为 ₹3.69b，因此如果需要，可能能够筹集足够的资本来巩固其资产负债表。然而，仔细观察其偿还债务的能力仍然是值得的。</p>
<p>查看我们对 ZIM Laboratories 的最新分析</p>
<p>我们通过查看公司的净债务与其息税折旧摊销前利润（EBITDA）的比率，以及计算其息税前利润（EBIT）覆盖利息支出的能力（利息覆盖率），来衡量公司的债务负担相对于其盈利能力的情况。这种方法的优点在于，我们考虑了债务的绝对数量（净债务与 EBITDA 的比率）以及与该债务相关的实际利息支出（其利息覆盖率）。</p>
<p>虽然我们不会担心 ZIM Laboratories 的净债务与 EBITDA 比率为 3.5，但我们认为其超低的利息覆盖率为 1.7 倍是高杠杆的迹象。显然，借款成本最近对股东的回报产生了负面影响。更糟的是，ZIM Laboratories 的 EBIT 在过去一年下降了 37%。如果盈利长期保持这种趋势，它几乎没有机会偿还这笔债务。在分析债务时，资产负债表显然是重点。但您不能完全孤立地看待债务；因为 ZIM Laboratories 需要盈利来偿还这笔债务。因此，如果您想了解更多关于其盈利的信息，查看其长期盈利趋势的图表可能是值得的。</p>
<p>最后，一家公司只能用现金偿还债务，而不是会计利润。因此，我们显然需要查看 EBIT 是否带来了相应的自由现金流。在过去三年中，ZIM Laboratories 消耗了大量现金。虽然这可能是由于增长支出的结果，但这确实使债务变得更加风险。</p>
<h2>我们的看法</h2>
<p>乍一看，ZIM Laboratories 将 EBIT 转换为自由现金流让我们对该股票持谨慎态度，其 EBIT 增长率也没有比一年中最繁忙的夜晚唯一空餐厅更具吸引力。话虽如此，其处理总负债的能力并不是一个大问题。总体而言，我们认为 ZIM Laboratories 的资产负债表对业务来说确实是一个风险。因此，我们对该股票持相当谨慎的态度，并认为股东应该密切关注其流动性。在分析债务水平时，资产负债表显然是一个起点。但最终，每家公司都可能存在资产负债表之外的风险。<strong>我们已经识别出 ZIM Laboratories 的 4 个警告信号</strong>（至少有 1 个可能是严重的），理解这些信号应该是您投资过程的一部分。</p>
<p>归根结底，通常更好的是关注没有净债务的公司。您可以访问我们特别列出的这些公司（所有公司都有盈利增长的记录）。这是免费的。</p>

<p>ZIM Laboratories (NSE:ZIMLAB) 的净债务为 11.3 亿印度卢比，而市场价值为 36.9 亿印度卢比，这引发了对其财务健康的担忧。公司的负债总额为 11.2 亿印度卢比，超过了现金和应收账款，公司的债务管理能力受到审视。其净债务与 EBITDA 的比率为 3.5，但 1.7 的低利息覆盖率表明杠杆率较高。此外，过去一年 EBIT 下降了 37%，进一步引发了对其偿债能力的担忧。总体而言，资产负债表存在风险，促使股东对流动性和债务管理保持谨慎</p>

<p>Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. We note that <strong>ZIM Laboratories Limited</strong> (NSE:ZIMLAB) does have debt on its balance sheet. But is this debt a concern to shareholders?</p>
<div class="lb-trans"><p>有些人认为波动性，而不是债务，是投资者思考风险的最佳方式，但沃伦·巴菲特曾著名地说过：“波动性远非风险的同义词。” 因此，聪明的钱知道，债务——通常与破产相关联——在评估一家公司风险时是一个非常重要的因素。我们注意到 <strong>ZIM Laboratories Limited</strong> (NSE:ZIMLAB) 的资产负债表上确实有债务。但这对股东来说是个问题吗？</p>
</div><p>This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.</p>
<div class="lb-trans"><p>这项技术可能会取代计算机：发现 20 只正在努力使量子计算成为现实的股票。</p>
</div><h2>What Risk Does Debt Bring?</h2>
<div class="lb-trans"><h2>债务带来什么风险？</h2>
</div><p>Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. If things get really bad, the lenders can take control of the business. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. The first step when considering a company's debt levels is to consider its cash and debt together.</p>
<div class="lb-trans"><p>债务在企业能够偿还时是有帮助的，无论是通过新资本还是自由现金流。如果情况变得非常糟糕，贷款方可能会控制企业。然而，更常见（但仍然痛苦）的情况是，公司不得不以低价筹集新的股本，从而永久性地稀释股东的权益。话虽如此，最常见的情况是公司合理管理其债务，并使其对自身有利。考虑公司债务水平的第一步是将其现金和债务一起考虑。</p>
</div><h2>How Much Debt Does ZIM Laboratories Carry?</h2>
<div class="lb-trans"><h2>ZIM Laboratories 的债务有多少？</h2>
</div><p>As you can see below, at the end of September 2025, ZIM Laboratories had ₹1.17b of debt, up from ₹973.5m a year ago. Click the image for more detail. On the flip side, it has ₹46.3m in cash leading to net debt of about ₹1.13b.</p>
<div class="lb-trans"><p>正如您在下面看到的，截至 2025 年 9 月底，ZIM Laboratories 的债务为 ₹1.17b，较一年前的 ₹973.5m 增加。点击图片以获取更多详细信息。另一方面，它有 ₹46.3m 的现金，导致净债务约为 ₹1.13b。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/58281653-debt-equity-history-analysis-1-dark-2/1768522290441" alt="" original-src="https://images.simplywall.st/asset/chart/58281653-debt-equity-history-analysis-1-dark-2/1768522290441"/></p>
<p>NSEI:ZIMLAB Debt to Equity History January 16th 2026</p>
<div class="lb-trans"><p>NSEI:ZIMLAB 债务与股本历史 2026 年 1 月 16 日</p>
</div><h2>How Healthy Is ZIM Laboratories' Balance Sheet?</h2>
<div class="lb-trans"><h2>ZIM Laboratories 的资产负债表健康吗？</h2>
</div><p>We can see from the most recent balance sheet that ZIM Laboratories had liabilities of ₹1.60b falling due within a year, and liabilities of ₹585.5m due beyond that. Offsetting these obligations, it had cash of ₹46.3m as well as receivables valued at ₹1.02b due within 12 months. So its liabilities total ₹1.12b more than the combination of its cash and short-term receivables.</p>
<div class="lb-trans"><p>我们可以从最新的资产负债表中看到，ZIM Laboratories 有 ₹1.60b 的负债在一年内到期，以及 ₹585.5m 的负债在此之后到期。抵消这些义务，它有 ₹46.3m 的现金以及价值 ₹1.02b 的应收账款将在 12 个月内到期。因此，它的负债总额比其现金和短期应收账款的总和多出 ₹1.12b。</p>
</div><p>This deficit isn't so bad because ZIM Laboratories is worth ₹3.69b, and thus could probably raise enough capital to shore up its balance sheet, if the need arose. However, it is still worthwhile taking a close look at its ability to pay off debt.</p>
<div class="lb-trans"><p>这个赤字并不算太糟，因为 ZIM Laboratories 的市值为 ₹3.69b，因此如果需要，可能能够筹集足够的资本来巩固其资产负债表。然而，仔细观察其偿还债务的能力仍然是值得的。</p>
</div><p>View our latest analysis for ZIM Laboratories</p>
<div class="lb-trans"><p>查看我们对 ZIM Laboratories 的最新分析</p>
</div><p>We measure a company's debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). The advantage of this approach is that we take into account both the absolute quantum of debt (with net debt to EBITDA) and the actual interest expenses associated with that debt (with its interest cover ratio).</p>
<div class="lb-trans"><p>我们通过查看公司的净债务与其息税折旧摊销前利润（EBITDA）的比率，以及计算其息税前利润（EBIT）覆盖利息支出的能力（利息覆盖率），来衡量公司的债务负担相对于其盈利能力的情况。这种方法的优点在于，我们考虑了债务的绝对数量（净债务与 EBITDA 的比率）以及与该债务相关的实际利息支出（其利息覆盖率）。</p>
</div><p>While we wouldn't worry about ZIM Laboratories's net debt to EBITDA ratio of 3.5, we think its super-low interest cover of 1.7 times is a sign of high leverage. It seems clear that the cost of borrowing money is negatively impacting returns for shareholders, of late. Worse, ZIM Laboratories's EBIT was down 37% over the last year. If earnings keep going like that over the long term, it has a snowball's chance in hell of paying off that debt. The balance sheet is clearly the area to focus on when you are analysing debt. But you can't view debt in total isolation; since ZIM Laboratories will need earnings to service that debt. So if you're keen to discover more about its earnings, it might be worth checking out this graph of its long term earnings trend.</p>
<div class="lb-trans"><p>虽然我们不会担心 ZIM Laboratories 的净债务与 EBITDA 比率为 3.5，但我们认为其超低的利息覆盖率为 1.7 倍是高杠杆的迹象。显然，借款成本最近对股东的回报产生了负面影响。更糟的是，ZIM Laboratories 的 EBIT 在过去一年下降了 37%。如果盈利长期保持这种趋势，它几乎没有机会偿还这笔债务。在分析债务时，资产负债表显然是重点。但您不能完全孤立地看待债务；因为 ZIM Laboratories 需要盈利来偿还这笔债务。因此，如果您想了解更多关于其盈利的信息，查看其长期盈利趋势的图表可能是值得的。</p>
</div><p>Finally, a company can only pay off debt with cold hard cash, not accounting profits. So we clearly need to look at whether that EBIT is leading to corresponding free cash flow. During the last three years, ZIM Laboratories burned a lot of cash. While that may be a result of expenditure for growth, it does make the debt far more risky.</p>
<div class="lb-trans"><p>最后，一家公司只能用现金偿还债务，而不是会计利润。因此，我们显然需要查看 EBIT 是否带来了相应的自由现金流。在过去三年中，ZIM Laboratories 消耗了大量现金。虽然这可能是由于增长支出的结果，但这确实使债务变得更加风险。</p>
</div><h2>Our View</h2>
<div class="lb-trans"><h2>我们的看法</h2>
</div><p>On the face of it, ZIM Laboratories's conversion of EBIT to free cash flow left us tentative about the stock, and its EBIT growth rate was no more enticing than the one empty restaurant on the busiest night of the year. Having said that, its ability to handle its total liabilities isn't such a worry. Overall, it seems to us that ZIM Laboratories's balance sheet is really quite a risk to the business. For this reason we're pretty cautious about the stock, and we think shareholders should keep a close eye on its liquidity. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. <strong>We've identified 4 warning signs</strong> with ZIM Laboratories (at least 1 which is potentially serious) , and understanding them should be part of your investment process.</p>
<div class="lb-trans"><p>乍一看，ZIM Laboratories 将 EBIT 转换为自由现金流让我们对该股票持谨慎态度，其 EBIT 增长率也没有比一年中最繁忙的夜晚唯一空餐厅更具吸引力。话虽如此，其处理总负债的能力并不是一个大问题。总体而言，我们认为 ZIM Laboratories 的资产负债表对业务来说确实是一个风险。因此，我们对该股票持相当谨慎的态度，并认为股东应该密切关注其流动性。在分析债务水平时，资产负债表显然是一个起点。但最终，每家公司都可能存在资产负债表之外的风险。<strong>我们已经识别出 ZIM Laboratories 的 4 个警告信号</strong>（至少有 1 个可能是严重的），理解这些信号应该是您投资过程的一部分。</p>
</div><p>At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.</p>
<div class="lb-trans"><p>归根结底，通常更好的是关注没有净债务的公司。您可以访问我们特别列出的这些公司（所有公司都有盈利增长的记录）。这是免费的。</p>
</div>

ZIM Laboratories（NSE:ZIMLAB）是否为一项高风险投资？